Literature DB >> 22740248

Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor β signaling.

Ikko Kajihara1, Masatoshi Jinnin, Noritoshi Honda, Katsunari Makino, Takamitsu Makino, Shinichi Masuguchi, Keisuke Sakai, Satoshi Fukushima, Yuji Inoue, Hironobu Ihn.   

Abstract

OBJECTIVES: Overexpression of vascular endothelial growth factor (VEGF) in scleroderma (SSc) skin may play a role in the pathogenesis of the disease. Our study was undertaken to evaluate whether dermal fibroblasts function as one of the sources of the increased VEGF in SSc, and to clarify its mechanism.
METHODS: Protein and mRNA levels of VEGF were analyzed using immunoblotting, enzyme-linked immunosorbent assay, and real-time PCR. The DNA-binding ability of Smad3 was evaluated by DNA affinity precipitation.
RESULTS: VEGF mRNA expression in vivo was increased in SSc skin compared to skin with other collagen diseases. Expression of VEGF protein and mRNA in cultured SSc dermal fibroblasts was constitutively and significantly upregulated. Ectopic TGF-β stimulation induced VEGF synthesis in normal fibroblasts, and TGF-β knockdown normalized the upregulated VEGF levels in SSc fibroblasts. Furthermore, Smad3 overexpression induced VEGF levels. We found that bp -532 to -521 on the VEGF promoter is a putative binding site for Smads, and that the binding activity of Smad3 to VEGF promoter was constitutively increased in SSc fibroblasts as well as in normal fibroblasts treated with exogenous TGF-β1.
CONCLUSIONS: We demonstrated that VEGF were overexpressed due to autocrine TGF-β/Smad signaling in SSc. TGF-β signaling may contribute to the pathogenesis of angiopathy as well as tissue fibrosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740248     DOI: 10.1007/s10165-012-0698-6

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

1.  Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis.

Authors:  Michael J Bollong; Baiyuan Yang; Naja Vergani; Brittney A Beyer; Emily N Chin; Claudio Zambaldo; Danling Wang; Arnab K Chatterjee; Luke L Lairson; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-17       Impact factor: 11.205

Review 2.  Fibroblasts in fibrosis: novel roles and mediators.

Authors:  Ryan T Kendall; Carol A Feghali-Bostwick
Journal:  Front Pharmacol       Date:  2014-05-27       Impact factor: 5.810

3.  Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement.

Authors:  Maria De Santis; Angela Ceribelli; Francesca Cavaciocchi; Chiara Crotti; Marco Massarotti; Laura Belloli; Bianca Marasini; Natasa Isailovic; Elena Generali; Carlo Selmi
Journal:  Auto Immun Highlights       Date:  2016-02-15

4.  Juvenile Localized Scleroderma with Hyaline Deposits in the Renal Arteriole.

Authors:  Nobuko Tabata; Chiyoko Nagano Inoue
Journal:  Case Rep Dermatol       Date:  2018-04-24

5.  Pathological mechanisms and therapeutic outlooks for arthrofibrosis.

Authors:  Kayley M Usher; Sipin Zhu; Georgios Mavropalias; John A Carrino; Jinmin Zhao; Jiake Xu
Journal:  Bone Res       Date:  2019-03-26       Impact factor: 13.567

Review 6.  Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts.

Authors:  Nicoletta Zoppi; Nicola Chiarelli; Marco Ritelli; Marina Colombi
Journal:  Int J Mol Sci       Date:  2018-03-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.